Notice
Huons BioPharma Secures Approval in Kuwait for Botulinum Toxin
Huons BioPharma Secures Approval in Kuwait for Botulinum Toxin
- Initial Entry into GCC Market, Accelerating Expansion across the Middle East -
Huons BioPharma, a Huons Group company specialized in botulinum toxin, expands its presence in the Middle East by securing approval from Kuwait.
Huons BioPharma Co., Ltd. (CEO Jeonghee Lee) announced on May 8 that the company has recently received approval from Ministry of Health Kuwait (MOH Kuwait) for its 100 units botulinum toxin product named Hutox (Korean brand name : LIZTOX).
This milestone was achieved through close collaboration with Huons BioPharma’s local Kuwaiti partner, AI Reyada. As Huons BioPharma’s first entry into the Gulf Cooperation Council (GCC) region, this approval will serve as a strategic bridgehead for expansion into the Middle East and the wider Gulf market.
Kuwait is widely recognized for its high demand for beauty and aesthetic treatments within the GCC region. Driven by a growing high-income consumer base and the rising popularity of non-invasive aesthetic procedures, the botulinum toxin market continues to see steady growth. In particular, with the market actively expanding around dermatology and aesthetic clinics, Kuwait stands as a country of high strategic importance.
Building on the recent approval in Kuwait, Huons BioPharma plans to expand its presence across the Middle East, including six GCC countries as the UAE, Saudi Arabia, Qatar, Oman, and Bahrain. Huons BioPharma aims to strengthen its global competitiveness by implementing tailored regulatory strategies and robust quality management systems designed to meet the specific requirements of each country.
Huons BioPharma has already secured regulatory approvals for its botulinum toxin product in 16 countries, supporting steady export growth. In January, Huons BioPharma has secured regulatory approval in China, marking the beginning of its full-scale entry into the Chinese market. Huons BioPharma is currently accelerating its global expansion, with regulatory approval processes proceeding smoothly across major emerging markets, including Latin America, Southeast Asia, and the Middle East.
CEO of Huons BioPharma, Jeonghee Lee said, “The recent approval in Kuwait once again proves Huons BioPharma’s global regulatory expertise and product competitiveness. Building on this momentum, we will continue to solidify our global standing by securing further approvals and scaling up our supply throughout the GCC and the Middle East.”
| No | title | Writer | date |
|---|---|---|---|
| 9 |
Huons Group Successfully Hosts Launch Symposium for Botulinum Toxin `Hutox` in China |
휴온스바이오파마 | 2026-07-20 |
| 8 |
Huons BioPharma Selected for Funding by the Korea Drug Development Fund to Advance Peptide Eye Drops for Dry Age-related Macular Degeneration. |
휴온스바이오파마 | 2026-06-23 |
| 7 |
Huons BioPharma Secures Approval in Kuwait for Botulinum Toxin |
휴온스바이오파마 | 2026-05-08 |
| 6 |
Huons BioPharma Appoints Jeonghee Lee as New CEO |
휴온스바이오파마 | 2026-04-14 |
| 5 |
Huons BioPharma Dispatches First Shipment of Botulinum Toxin to China |
휴온스바이오파마 | 2026-03-16 |
| 4 |
Huons BioPharma Secures NMPA Approval for Type A Botu-linum Toxin in China |
휴온스바이오파마 | 2026-01-09 |
| 3 |
Three Affiliates of Huons Group Honored with Export Tower Awards on Trade Day |
휴온스바이오파마 | 2025-12-08 |
| 2 |
Huons BioPharma Received Award for ‘2025 Excellent Employment’ in Chungcheongbuk-do |
휴온스바이오파마 | 2025-11-05 |
| 1 |
Huons Biopharma and VERNI Aesthetics Sign 'Aesthetic Enhancement' Agreement |
휴온스바이오파마 | 2024-11-29 |